DECLARATION OF COMPLIANCE 2026

Declaration of Compliance by the Executive Board and the Supervisory Board of Leo International Precision Health Aktiengesellschaft regarding the recommendations of the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

The Management Board and Supervisory Board of Leo International Precision Health Aktiengesellschaft declare that the recommendations of the "Government Commission on the German Corporate Governance Code" in the version dated April 28, 2022 ("DCGK") have been complied with since the submission of the last declaration of conformity on April 22, 2025, with the exception of the deviations listed below, and that these recommendations will continue to be complied with in the future, with the exception of the deviations listed below:

Section A1.

The DCGK recommends systematically identifying and assessing the risks and opportunities for the company associated with social and environmental factors, as well as the environmental and social impacts of the company's activities. In addition to long-term economic goals, the corporate strategy should also give appropriate consideration to environmental and social goals. Corporate planning should include corresponding financial and sustainability-related goals.

Taking into account the size, structure and current stage of development of the Company, specific financial or sustainability-related targets are currently not formally defined within corporate planning. The Company assesses social and environmental aspects in accordance with applicable legal requirements and shall further develop corresponding processes as required by law.

Section B.1

The DCGK recommends ensuring diversity in the composition of the Executive Board.

When appointing members to the Executive Board, the Supervisory Board considers the suitability of the available candidates. Furthermore, the Executive Board has an international composition.

Section F.2

The DCGK recommends that the consolidated financial statements and the consolidated management report be made publicly available within 90 days of the end of the fiscal year, and that the mandatory interim financial information be made publicly available within 45 days of the end of the reporting period.

In light of the absence of binding statutory harmonization between the publication deadlines set out in the German Corporate Governance Code and those under applicable law, and considering the Company's operational circumstances, publication timelines may deviate from the recommended periods. Such deviations are permissible under Section 161 of the German Stock Corporation Act (AktG) and are disclosed transparently through this declaration.

As long as there is no uniform regulation regarding the statutory publication deadlines and those of the DCGK, the Company reserves the right to deviate from Section F.2.

Sections G.6 through G.12

The DCGK contains recommendations regarding the structure of variable compensation for members of the Management Board.

The Management Board currently receives no variable compensation, so the recommendations in Sections G.6 through G.12 do not apply.

Section G.17

The DCGK recommends that the greater time commitment of the Chairman of the Supervisory Board and his or her deputy be appropriately compensated.

Given the current scale of operations and organizational structure of the Company, the Supervisory Board has determined that differentiated compensation for the Chairman of the Supervisory Board and his or her deputy is currently not considered necessary. This assessment may be revisited should the Company's circumstances materially change.

Planegg / Martinsried, 21 April 2026

Leo International Precision Health Aktiengesellschaft

For the Management Board

Dr. Joshua Lo

Chief Executive Officer

For the Supervisory Board

Leo Wang

Chairman of the Supervisory Board